Premium
IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL
Author(s) -
Langerbeins P.,
Bahlo J.,
Rhein C.,
Gerwin H.,
Cramer P.,
Fürstenau M.,
AlSawaf O.,
Tresckow J.,
Fink A.M.,
Kreuzer K.,
VehlingKaiser U.,
Tausch E.,
Müller L.,
Eckart M.,
Schlag R.,
Freier W.,
Gaska T.,
Balser C.,
Reiser M.,
Stauch M.,
Wendtner C.,
Fischer K.,
Stilgenbauer S.,
Eichhorst B.,
Hallek M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.7_2629
Subject(s) - ibrutinib , medicine , clinical endpoint , asymptomatic , placebo , randomization , randomized controlled trial , oncology , chronic lymphocytic leukemia , leukemia , pathology , alternative medicine